Nuveen’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$300M Sell
5,212,215
-601,418
-10% -$34.5M 0.07% 204
2026
Q1
$353M Buy
5,813,633
+287,372
+5% +$16.8M 0.1% 168
2025
Q4
$298M Sell
5,526,261
-473,495
-8% -$22.8M 0.08% 198
2025
Q3
$271M Sell
5,999,756
-321,605
-5% -$15M 0.07% 223
2025
Q2
$293M Sell
6,321,361
-3,915,868
-38% -$192M 0.08% 207
2025
Q1
$624M Sell
10,237,229
-183,716
-2% -$10.7M 0.19% 99
2024
Q4
$589M Buy
10,420,945
+1,444,822
+16% +$80.7M 0.17% 107
2024
Q3
$464M Buy
8,976,123
+3,434,182
+62% +$161M 0.13% 139
2024
Q2
$230M Sell
5,541,941
-4,407,780
-44% -$197M 0.07% 227
2024
Q1
$540M Sell
9,949,721
-756,035
-7% -$38.5M 0.16% 121
2023
Q4
$549M Sell
10,705,756
-644,574
-6% -$33.8M 0.18% 111
2023
Q3
$659M Sell
11,350,330
-3,653,431
-24% -$224M 0.23% 96
2023
Q2
$959M Sell
15,003,761
-1,330,078
-8% -$89.2M 0.33% 64
2023
Q1
$1.13B Sell
16,333,839
-1,257,704
-7% -$88.7M 0.42% 51
2022
Q4
$1.27B Buy
17,591,543
+968,998
+6% +$73.1M 0.49% 44
2022
Q3
$1.18B Buy
16,622,545
+865,053
+5% +$62.8M 0.48% 38
2022
Q2
$1.21B Buy
15,757,492
+2,226,874
+16% +$170M 0.47% 40
2022
Q1
$961M Buy
13,530,618
+410,317
+3% +$27.6M 0.31% 64
2021
Q4
$818M Sell
13,120,301
-884,926
-6% -$51.9M 0.24% 89
2021
Q3
$829M Sell
14,005,227
-723,903
-5% -$47.7M 0.26% 83
2021
Q2
$984M Buy
14,729,130
+328,973
+2% +$21.5M 0.29% 70
2021
Q1
$909M Sell
14,400,157
-157,862
-1% -$9.82M 0.29% 70
2020
Q4
$903M Buy
14,558,019
+1,365,694
+10% +$84M 0.31% 64
2020
Q3
$795M Sell
13,192,325
-34,499
-0.3% -$2.08M 0.31% 69
2020
Q2
$778M Sell
13,226,824
-4,992,608
-27% -$299M 0.32% 68
2020
Q1
$1.02B Sell
18,219,432
-3,091,390
-15% -$189M 0.49% 38
2019
Q4
$1.37B Buy
21,310,822
+11,327,720
+113% +$649M 0.52% 33
2019
Q3
$506M Buy
9,983,102
+587,982
+6% +$27.6M 0.2% 101
2019
Q2
$426M Buy
9,395,120
+9,332,319
+14,860% +$435M 0.17% 122
2019
Q1
$3M Buy
62,801
+8,059
+15% +$401K 0.02% 583
2018
Q4
$2.85M Buy
54,742
+182
+0.3% +$9.78K 0.02% 571
2018
Q3
$3.39M Sell
54,560
-1,395
-2% -$82.8K 0.02% 566
2018
Q2
$3.1M Sell
55,955
-40,922
-42% -$2.21M 0.02% 546
2018
Q1
$6.13M Sell
96,877
-157,239
-62% -$10.1M 0.04% 459
2017
Q4
$15.6M Buy
254,116
+191,370
+305% +$12M 0.1% 303
2017
Q3
$4M Hold
62,746
0.03% 509
2017
Q2
$3.5M Sell
62,746
-26,533
-30% -$1.44M 0.02% 530
2017
Q1
$4.86M Sell
89,279
-127,979
-59% -$7.02M 0.03% 518
2016
Q4
$12.7M Buy
217,258
+13,961
+7% +$763K 0.06% 387
2016
Q3
$11M Sell
203,297
-3,116
-2% -$200K 0.06% 365
2016
Q2
$15.2M Sell
206,413
-9,500
-4% -$671K 0.09% 265
2016
Q1
$13.8M Sell
215,913
-9,206
-4% -$581K 0.07% 280
2015
Q4
$15.5M Buy
225,119
+34,099
+18% +$2.25M 0.08% 258
2015
Q3
$11.3M Sell
191,020
-5,441
-3% -$345K 0.06% 308
2015
Q2
$13.1M Sell
196,461
-24,913
-11% -$1.64M 0.07% 326
2015
Q1
$14.3M Buy
221,374
+1,327
+0.6% +$83.1K 0.08% 326
2014
Q4
$13M Buy
220,047
+100,297
+84% +$5.66M 0.07% 340
2014
Q3
$6.13M Sell
119,750
-197,082
-62% -$9.84M 0.04% 482
2014
Q2
$15.4M Sell
316,832
-134,271
-30% -$6.62M 0.09% 286
2014
Q1
$23.4M Buy
451,103
+55,997
+14% +$2.98M 0.14% 190
2013
Q4
$21M Sell
395,106
-14,524
-4% -$740K 0.14% 220
2013
Q3
$19M Sell
409,630
-44,959
-10% -$1.97M 0.12% 227
2013
Q2
$20.3M Buy
+454,589
New +$19.7M 0.14% 211

Other funds holding BMY

Nuveen's BMY Position: Q2 2026 in Review

Nuveen reduced its Bristol-Myers Squibb (BMY) stake by 10% in Q2 2026, selling an estimated $34.5M and leaving 5,212,215 shares worth $300M. The position accounts for 0.07% of the portfolio, ranked #204.

Nuveen first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.37B in Q4 2019. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Nuveen held 5,212,215 shares of Bristol-Myers Squibb worth $300M as of Q2 2026.
  • Nuveen sold 601,418 Bristol-Myers Squibb shares in Q2 2026, an estimated $34.5M.
  • Bristol-Myers Squibb made up 0.07% of Nuveen's portfolio in Q2 2026, its #204 holding.
  • Nuveen first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Nuveen's Bristol-Myers Squibb position peaked at $1.37B in Q4 2019.
  • 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.